CN100409850C - 2h-[1,3]-噁嗪并[3,2-a]吲哚衍生物在制备治疗神经性疼痛的药物中的用途 - Google Patents

2h-[1,3]-噁嗪并[3,2-a]吲哚衍生物在制备治疗神经性疼痛的药物中的用途 Download PDF

Info

Publication number
CN100409850C
CN100409850C CNB2004800172642A CN200480017264A CN100409850C CN 100409850 C CN100409850 C CN 100409850C CN B2004800172642 A CNB2004800172642 A CN B2004800172642A CN 200480017264 A CN200480017264 A CN 200480017264A CN 100409850 C CN100409850 C CN 100409850C
Authority
CN
China
Prior art keywords
neuropathic pain
pain
treatment
compound
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004800172642A
Other languages
English (en)
Chinese (zh)
Other versions
CN1809361A (zh
Inventor
A·古列尔莫蒂
L·波伦扎尼
A·阿利希
N·卡佐拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angelini Acraf SpA
Original Assignee
Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco ACRAF SpA filed Critical Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Publication of CN1809361A publication Critical patent/CN1809361A/zh
Application granted granted Critical
Publication of CN100409850C publication Critical patent/CN100409850C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNB2004800172642A 2003-07-18 2004-07-08 2h-[1,3]-噁嗪并[3,2-a]吲哚衍生物在制备治疗神经性疼痛的药物中的用途 Expired - Fee Related CN100409850C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001467A ITMI20031467A1 (it) 2003-07-18 2003-07-18 Farmaco attivo nel dolore neuropatico
ITMI2003A001467 2003-07-18

Publications (2)

Publication Number Publication Date
CN1809361A CN1809361A (zh) 2006-07-26
CN100409850C true CN100409850C (zh) 2008-08-13

Family

ID=34131193

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800172642A Expired - Fee Related CN100409850C (zh) 2003-07-18 2004-07-08 2h-[1,3]-噁嗪并[3,2-a]吲哚衍生物在制备治疗神经性疼痛的药物中的用途

Country Status (20)

Country Link
US (1) US20060211691A1 (https=)
EP (1) EP1646391B1 (https=)
JP (1) JP2006528142A (https=)
KR (1) KR20060033784A (https=)
CN (1) CN100409850C (https=)
AR (1) AR045993A1 (https=)
AT (1) ATE345137T1 (https=)
AU (1) AU2004262876B2 (https=)
CA (1) CA2526852C (https=)
DE (1) DE602004003252T2 (https=)
DK (1) DK1646391T3 (https=)
EA (1) EA008927B1 (https=)
ES (1) ES2276317T3 (https=)
GE (1) GEP20084307B (https=)
IL (1) IL172156A0 (https=)
IT (1) ITMI20031467A1 (https=)
PL (1) PL1646391T3 (https=)
PT (1) PT1646391E (https=)
UA (1) UA81050C2 (https=)
WO (1) WO2005014001A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5023074B2 (ja) * 2006-12-26 2012-09-12 大鵬薬品工業株式会社 糖尿病性ニューロパチー治療剤
DE102007058504A1 (de) 2007-12-05 2009-07-09 Acino Ag Transdermales therapeutisches System mit einem Gehalt an einem Modulator für nikotinische Acetylcholinrezeptoren (nAChR)
WO2025077825A1 (en) * 2023-10-13 2025-04-17 Fauna Bio Incorporated Methods and compositions for treating cardio-pulmonary disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1078471A (zh) * 1992-03-12 1993-11-17 史密丝克莱恩比彻姆有限公司 药品
CN1183041A (zh) * 1995-03-16 1998-05-27 伊莱利利公司 吲唑甲酰胺

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189041A (en) * 1990-11-16 1993-02-23 Syntex (U.S.A.) Inc. Tricyclic 5-ht3 receptor antagonists
GB9120628D0 (en) * 1991-09-27 1991-11-06 Fujisawa Pharmaceutical Co Pyrrolobenzoxazine derivatives and process for preparation thereof
NZ527771A (en) * 1999-08-04 2005-04-29 Icagen Inc Methods for treating or preventing anxiety
US20040038874A1 (en) * 2002-08-22 2004-02-26 Osemwota Omoigui Method of treatment of persistent pain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1078471A (zh) * 1992-03-12 1993-11-17 史密丝克莱恩比彻姆有限公司 药品
CN1183041A (zh) * 1995-03-16 1998-05-27 伊莱利利公司 吲唑甲酰胺
US5817676A (en) * 1995-03-16 1998-10-06 Eli Lilly And Company Indazolecarboxamides

Also Published As

Publication number Publication date
GEP20084307B (en) 2008-02-11
EP1646391A1 (en) 2006-04-19
CN1809361A (zh) 2006-07-26
UA81050C2 (en) 2007-11-26
HK1087027A1 (en) 2006-10-06
AR045993A1 (es) 2005-11-23
JP2006528142A (ja) 2006-12-14
WO2005014001A1 (en) 2005-02-17
CA2526852A1 (en) 2005-02-17
DK1646391T3 (da) 2007-03-19
EA200600270A1 (ru) 2006-06-30
DE602004003252T2 (de) 2007-05-03
AU2004262876A1 (en) 2005-02-17
EA008927B1 (ru) 2007-08-31
ATE345137T1 (de) 2006-12-15
WO2005014001A9 (en) 2005-05-26
ES2276317T3 (es) 2007-06-16
DE602004003252D1 (de) 2006-12-28
IL172156A0 (en) 2006-04-10
CA2526852C (en) 2011-08-30
AU2004262876B2 (en) 2010-05-20
ITMI20031467A1 (it) 2005-01-19
US20060211691A1 (en) 2006-09-21
EP1646391B1 (en) 2006-11-15
PT1646391E (pt) 2007-01-31
PL1646391T3 (pl) 2007-04-30
KR20060033784A (ko) 2006-04-19

Similar Documents

Publication Publication Date Title
US8268892B2 (en) Pharmaceutical formulations of modafinil
US20080226715A1 (en) Therapeutic compositions and methods
KR20030016205A (ko) Ｃｎｓ 질환의 치료를 위한 단독 또는 조합된피롤리딘아세트아미드 유도체
JP2002524498A (ja) 機能性及び／又は器質性痛み症候群の治療のための製薬組成物の調製のためのアセチルコリンエステラーゼ阻害剤の使用
CN100409850C (zh) 2h-[1,3]-噁嗪并[3,2-a]吲哚衍生物在制备治疗神经性疼痛的药物中的用途
US20050089558A1 (en) Compositions and methods for the co-formulation and administration of tramadol and propoxyphene
KR101073993B1 (ko) 신경병증성 통증의 치료를 위한 인다졸 유도체의 용도
KR20230047412A (ko) 진통 가려움 완화 약학 조성물 및 그 응용 방법
JP7656339B2 (ja) 疼痛を緩和するためのイブプロフェン及びトラマドールの組合せ
HK1087027B (en) Use of 2h-[1, 3]-oxazino[3,2-a]indole derivatives for the treatment of neuropathic pain
KR20220110259A (ko) 통증 질환에 사용하기 위한 미르타자핀 및 티자니딘 배합물
MXPA06000677A (es) Uso de derivados de 2h-[1,3]-oxazino [3,2-a]indol para el tratamiento de dolor neuropatico
HK40067137A (en) Combination of ibuprofen and tramadol for relieving pain
HK40067137B (en) Combination of ibuprofen and tramadol for relieving pain
WO2002043727A1 (en) Treatment of psychiatric disorders with trimethyl-bicyclo[2.2.1]heptane derivatives
JP2004168692A (ja) ４−（２−フルオロフェニル）−６−メチル−２−（１−ピペラジニル）チエノ［２，３−ｄ］ピリミジンの新規な用途
WO2002056868A2 (en) Method for treating stress or tension

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080813

Termination date: 20120708